TGF-β signal transduction inhibitor
US8772297B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 17, 2011 |
| Grant date | Jul 8, 2014 |
| Priority date | — |
| Expiry date | Feb 17, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound represented by the following formula (I) or a physiologically acceptable salt thereof, and use thereof for the prophylaxis or treatment of TGF-β-related diseases:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.